Developing a Novel Dual-functional Antibody-drug Conjugates against Growth Hormone and Prolactin for Breast Cancer Treatment

FIRST NAMED INVESTIGATOR: Dr. Yue Wang
HOST INVESTIGATOR: University of Auckland

Problem
Breast cancer is the most common cancer in women worldwide, but it’s hard to treat because it’s complicated and can resist treatments. Two hormones—growth hormone (GH) and prolactin—can make cancer cells grow faster. Higher levels of these hormones are linked to worse outcomes for patients.

Project
This project is testing a new treatment that targets both GH and prolactin at the same time. Right now, treatments focus on blocking one of these hormones, but they haven’t worked very well. The goal is to create a drug that stops both hormones from helping cancer cells grow.

Outcome
If successful, this new treatment could slow down the growth of tumors, even in cases where current treatments aren’t working. It could improve the outcomes for breast cancer patients and help fight the resistance that some treatments face.

Future
This research could lead to a better, more effective treatment for breast cancer, helping patients who haven’t responded to other therapies and offering hope for the future of cancer treatment.